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ABSTRACT 
Context: Breast cancer chemoprevention is recognized as an effective strategy 
for risk reduction in women at high risk for the future development of breast 
cancer. Women with a history of breast biopsy revealing atypical hyperplasia or 
lobular carcinoma in situ are at particularly high risk for developing breast cancer. 
The rates of chemoprevention counseling and prescribing in this population are 
unknown. 
Objective: To determine the practice patterns of general surgeons who perform 
breast biopsies with regard to breast cancer chemoprevention counseling and 
prescribing. 
Design: Cross-sectional descriptive study based on the results of a self-
administered questionnaire mailed to general surgeons. 
Participants: General surgeons living in and licensed to practice in North 
Carolina. In the data analysis, we will exclude those respondents whose practice 
does not include breast care. 
Main Outcome Measures: Rates of breast cancer chemoprevention counseling 
and prescribing. Description of surgeon and practice characteristics related to 
counseling and prescribing. Description of referral patterns for chemoprevention 
counseling and prescribing. 
Results: Pending at this time. Once data collection is complete, we may 
anticipate the following results: 
I. Surgeons are not discussing chemoprevention with high risk patients OR 
2. Surgeons discuss or recommend chemoprevention but do not prescribe it OR 
3. Surgeons discuss and prescribe chemoprevention 
Conclusions: If surgeons are not discussing chemoprevention with high risk 
patients, an educational intervention may be appropriate. If surgeons discuss 
chemoprevention but refer to another provider for prescribing, it will be necessary 
to survey these other providers to determine if patients are getting 
chemoprevention medications. If we fmd high rates of chemoprevention 
counseling and prescribing in North Carolina, repeating the survey on a national 
level would define geographic variations. 
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INTRODUCTION 
Breast cancer presents a significant public health problem. The American 
Cancer Society estimates that 211,300 women will be diagnosed with invasive 
breast cancer and 55,700 will be diagnosed with in situ cancer in the US in 2003. 
Almost 40,000 deaths are expected.1 In North Carolina, 6385 cases and 1370 
deaths are expected in 2003.2 Risk factors for breast cancer include increasing 
age, previous diagnosis of breast cancer, family history of breast cancer, young 
age at menses, older age at first birth, nulliparity, and history of breast biopsy. In 
particular, a breast biopsy revealing atypical ductal hyperplasia (ADH) or lobular 
carcinoma in situ (LCIS) places a woman at significantly increased risk. 
Because there are few modifiable risk factors for breast cancer, early 
detection has been the principle approach to breast cancer control. Recently, 
preventive efforts have focused on using medications to decrease a woman's risk 
of breast cancer. This is known as chemoprevention. Breast cancer treatment 
studies found the incidence of contralateral breast cancers in women treated with 
tarnoxifen to be much lower than expected. This led to the idea that tarnoxifen 
may be effective as a chemopreventive agent. Several large clinical trials of 
tarnoxifen for breast cancer chemoprevetion found that the drug does prevent 
some breast cancers, especially in women at high risk for developing the disease. 
Histopathologic factors found on benign breast biopsies place a patient at 
increased risk for the future development of breast cancer. These include the 
atypical hyperplasias and lobular carcinoma in situ. Atypical hyperplasia is a 
breast lesion that has some but not all of the features of carcinoma in situ. 
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Current pathologic classification divides the atypical hyperplasias into atypical 
ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). Lobular 
carcinoma in situ (LCIS) is a lesion generally considered to be a marker for 
increased risk of future breast cancer. These histopathologic changes are present 
in 5-l 0% of all breast biopsy specimens. 
Chemoprevention is one of three treatment options for women with a 
breast biopsy revealing atypical hyperplasia or LCIS. The other two are careful 
surveillance with regular marmnograms and clinical breast exams, and bilateral 
prophylactic mastectomy. Surveillence is the most common option. Mastectomy 
is reserved for those women who have intense fear and distress about breast 
cancer? The rate of chemoprevention use in this high risk population of patients I is unknown. 
BACKGROUND 
Pathology and Future Risk of Breast Cancer 
The evolution of premalignant breast disease into invasive breast cancer is 
not completely understood. There may be a continuum of carcinogenesis from 
normal terminal duct lobular units to ADH/ALH to DCIS/LCIS to invasive 
cancer. Many genetic changes have been identified in the atypical hyperplasias, 
including loss of heterozygosity, allelic imbalance, p53 tumor suppressor gene 
mutations and estrogen receptor overexpression. In fact, 95% of samples of ADH 
and LCIS overexpress the estrogen receptor.4 This may explain why tamoxifen, a 
drug that acts as an antiestrogen, is more effective in preventing breast cancer in 
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those women with ADH or LCIS as compared to the high-risk population as a 
whole. 
The atypical hyperplasias and LCIS were historically considered to be 
markers of increased risk overall, rather than premalignant lesions themselves. 
However, review ofthe literature shows that in some series the increased risk was 
actually about two-thirds in the ipsilateral breast and one-third in the contralateral 
breast. Recently published results from the Nashville Breast Studies found the 
risk of invasive cancer following ALH to be almost three times higher in the 
ipsilateral breast. According to the authors, "Our findings suggest a model of 
premalignancy for ALH intermediate between a local precursor and a generalized 
risk for both breasts. "5 
In the pre-manunographic era, the prevalence of atypical hyperplasia in 
benign breast biopsies was 4 - 5%. The prevalence increases to approximately 
10% of benign biopsies in the manunographically-screened population.6 In a 
sample within the Nurses Health Study, the mean age of biopsy revealing atypical 
hyperplasia was 4 3 years and the time from first biopsy to diagnosis of breast 
cancer was 8-10 years.7 In the Nashville Breast Studies, invasive breast cancer 
was diagnosed 14.8 years after biopsy showing ALH. 5 
In a case-control study done within the Breast Cancer Detection and 
Demonstration Project, atypical hyperplasia increased the risk of future 
development of breast cancer by four times (OR=4.3, 95% CI 1.7-11). This is 
consistent with a previous study by the same authors that found the odds of breast 
cancer increased 5.3 times compared to benign biopsies without proliferative 
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disease. History of breast cancer in a first degree relative doubled the risk of 
breast cancer, and appears to be synergistic with atypical hyperplasia. Thus, in a 
woman with a family history of breast cancer and a biopsy with atypical 
hyperplasia, the odds of breast cancer are eight to ten times higher than the 
general population. 6 
A nested case-control study of biopsy-confirmed breast disease in a cohort 
within the Nurses Health Study divided the atypical hyperplasias into atypical 
ductal hyperplasia and atypical lobular hyperplasia. Overall, atypical hyperplasia 
increased the risk of breast cancer 3.4 times (95% CI, 2.0-5.9). ALH increased 
the risk of breast cancer (OR=5.3, 95% CI, 2.7-10.4) more than ADH (OR=2.4, 
95% CI, 1.3-4.5). The difference between the two was significant (p=0.05).7 
The absolute risk of invasive breast cancer following a biopsy with 
atypical hyperplasia is reported to be 10-15% in 15-20 years. In a patient with 
atypical hyperplasia and one first degree relative with breast cancer, the absolute 
risk increases to 20-30% over the next 15-20 years. By contrast, the absolute risk 
of invasive breast cancer in a woman who carries the BRCA-1 mutation is 80-
85%.8 
Lobular carcinoma in situ is less common than the atypical hyperplasias. 
It represents 0.5% of symptomatic and 1% of screen-detected breast lesions. The 
absolute risk of invasive breast cancer following a diagnosis of LCIS is 25-40% in 
15-20 years. Over that time period, the absolute risk of breast cancer in the same 
breast is 15-20% and it is 10-15% in the contralateral breast.8 
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Tamoxifen 
Tamoxifen is a selective estrogen receptor modulator that has 
antiestrogenic effects on breast tissue and estrogenic effects on bone, 
endometrium, lipids and clotting. In the breast, it is a nonsteroidal antiestrogen 
that competitively inhibits estrogen binding to the estrogen receptor. Thus, it 
modulates the expression of estrogen related genes that influence breast cell 
growth and apoptosis. 9 It increases natural killer cell activity and antibody 
production. It decreases insulin-like growth factor and increases TGF-beta. 10 It is 
effective in the prevention and treatment of breast cancers that overexpress the 
estrogen receptor (ER+). Overall, 60-70% of breast cancers are ER+ --50% of 
premenopausal cancers and 80% ofpostmenopauseal cancers.9 
T amoxifen has been shown to decrease the incidence of breast cancer in 
three important clinical settings. Women with invasive breast cancer who are 
treated with tamoxifen have a 4 7% reduced incidence of contralateral breast 
cancer.11 In women with DCIS, the addition oftamoxifen following lumpectomy 
and whole breast radiation therapy decreases the incidence of invasive and non-
invasive carcinoma in both the ipsilateral and contralateral breasts.12 Finally, in 
women at elevated risk for the future development of breast caner, tamoxifen 
prevents 69% of estrogen-receptor positive tumors. 13 
Tamoxifen, approved by the FDA for treatment of metastatic breast cancer 
in 1977, has a favorable side-effect profile when viewed as a breast cancer 
treatment drug. However, when viewed as a preventive agent, the side effects 
seem more significant. Side effects of tamoxifen include climacteric symptoms, 
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increased risk of endometrial cancer, increased thromboembolic events (stroke, 
deep vein thrombosis, pulmonary embolism) and increased cataracts. Tamoxifen 
use is associated with decreased fractures. It does not appear to have any effect 
on heart disease, liver cancer, colorectal cancer or ovarian cancer. 13 
Foil owing the results of the Breast Cancer Prevention Trial (BCPT), 
tamoxifen received FDA approval for breast cancer risk reduction. Tamoxifen is 
the first drug to get FDA approval for the primary prevention of cancer.9 It is 
approved for use in both premenopausal and postmenopausal women age 35 and 
older whose five-year risk of breast cancer is greater than or equal to that of the 
average 60 year old. This corresponds to a Gail risk score of> 1.66%.14 
Tamoxifen reduces the risk of developing estrogen-receptor positive breast 
cancer by 69%. It has no effect on the incidence of estrogen-receptor negative 
tumors. Estrogen-receptor positive tumors occur in 51% of premenopausal 
women and in 80% of postmenopausal women. 14 Thus, tamoxifen is potentially 
more beneficial in postmenopausal women. However, the adverse events 
associated with tamoxifen also increase with age. 
In the BCPT, tamoxifen also reduced the incidence of benign breast 
disease (RR= 0.72, 95% CI 0.65-0.79) and reduced the number of breast biopsies 
in the treatment group (RR=0.71, 95% CI 0.66-0.77). The risk was especially 
decreased in women less than 50 years old. There was also a decrease in 
symptomatic complaints of breast pain and swelling.15 
CHEMOPREVENTION TRIALS 
8 
' L 
I 
I 
In the evidence summary performed for the United States Preventive 
Services Task Force (USPSTF), Kinsinger at al. 16 examined the benefits and 
harms of breast cancer chemoprevention. Four randomized controlled trials were 
included in the analysis: the Royal Marsden Hospital Tamoxifen 
Chemoprevention Trial; the Italian Tamoxifen Prevention Study; the Breast 
Cancer Prevention Trial (BCPT); and the Multiple Outcomes ofRaloxifene 
Evaluation (MORE). A fourth tamoxifen trial, the International Breast Cancer 
Intervention Study (IBIS-1) has since been completed. The authors concluded 
that the evidence supports a substantial effect of chemoprevention in reducing the 
incidence of estrogen-receptor positive tumors. Based on the results of this 
summary, the USPSTF recommends that clinicians discuss breast cancer 
chemoprevention with all women who are at high risk for breast cancer and at low 
risk for adverse events. 
The four tamoxifen prevention trials and the single raloxifene prevention 
trial will now be reviewed in more detail. 
Breast Cancer Prevention Trial 
The largest trial of tamoxifen for breast cancer chemoprevention is the 
National Surgical Adjuvant Breast and Bowel Project (NSABP) P-Ol Trial, 13 also 
known as the Breast Cancer Prevention Trial (BCPT). The BCPT randomized 
13,388 high-risk women either to treatment with tamoxifen (20mg/day for 5 
years) or to placebo. In this trial, high-risk was defined as 1) age greater than or 
equal to 60 years; 2) history oflobular carcinoma in situ; or 3) age 35-59 with a 
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five-year modified Gail model risk of at least 1.66%. Of these women, 6.3% had 
a history ofLCIS and 9.1% had a history of ADH. Overall, invasive breast cancer 
was reduced 49% (RR=0.51, 95% CI 0.39-0.66). Through 69 months of follow-
up, the cumulative incidence of invasive breast cancer was 43.4 cases per 1000 
women in the placebo group and 22.0 cases per 1000 women in the treatment 
group. Absolute 5-year risk decreased from 2.6% in the placebo group to 1.3% in 
the treatment group. Tamoxifen reduced the occurrence of in situ breast cancer 
(DCIS and LCIS combined) by 50% (RR=0.50, 95% CI 0.33-0.77). The 
reduction in breast cancer cases comprised estrogen-receptor positive, but not 
estrogen-receptor negative, tumors. 
Specifically, in the group with a history of LCIS, breast cancer was 
reduced 56% (RR=0.44, 95% CI 0.16-1.06) and in the group with a history of 
ADH, breast cancer decreased by 86% (RR= 0.14, 95% CI 0.03-0.47). One 
possible explanation for this is that LCIS and ADH are most often estrogen-
receptor positive. The BCPT is the only one of the four to report subgroup 
analysis ofLCIS and ADH patients. 
There were meaningful risks associated with tamoxifen use (see Table 1). 
Specifically, the treatment group had higher rates of endometrial cancer, stroke, 
deep vein thrombosis, pulmonary embolus and cataracts. These adverse events 
were more common in women older than 50 years. There was no increase in the 
incidence of other cancers or ischemic heart disease. There was a non-statistically 
significant decrease in fractures of the hip and radius in the treatment group. 
Overall quality oflife scores were similar between the two groups, although 
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women in the treatment group reported significantly more bothersome hot flashes 
and vaginal discharge. 
TABLE 1: RISKS AND BENEFITS OF TAMOXIFEN IN THE BCPT 
Event Rate/1000 women Rate/1 000 women Relative 
Placebo Tarnoxifen Risk 
Endometrial Cancer 0.91 2.30 2.53* 
Stroke 0.92 1.45 1.59* 
Deep Vein Thrombosis 084 1.34 1.60 
Pulmonary Embolus 0.23 0.69 3.01 * 
Cataracts 21.72 24.82 1.14* 
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Fractures 5.28 4.29 0.81 
Noninvasive Breast 15.9 7.7 0.50* 
Cancer 
Invasive Breast Cancer 43.4 22.0 0.51* 
* statiStically significant 
Methodologically, the BCPT is the strongest of the 4 trials. It is the 
largest and attrition was much lower than in the other studies. In fact, the 
combination of a lower-than-expected occurrence of breast cancer events and the 
high rate of attrition likely left the European studies underpowered to detect a 
difference. The BCPT had strict, well-defined inclusion and exclusion criteria. 
Specifically, "high-risk" was rigorously defined. Most importantly, women in the 
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BCPT were not allowed to take hormone replacement therapy (HRT) 
concurrently. The European trials did allow enrolled women to take HRT. 
Allowing enrolled women to take estrogen supplements at the same time confuses 
the results in two ways. First, given that tamoxifen' s action as a breast cancer 
preventive agent is likely because of its anti-estrogenic effects, the combination of 
an anti-estrogen with estrogen supplementation leads to unknown biologic effects. 
Second, the results of the Women's Health Initiative now show that HRT use is 
associated with an increased incidence of breast cancer.17 
The BCPT does not address low-to-average risk patients. A major 
weakness of the study is that 96.5% of those enrolled were white; the risk 
reduction seen in this study may not be generalizable to non-whites. Also, it does 
not include a subset analysis of women with BRCAl or BRCA2 mutations, and so 
it does not contribute to our understanding oftamoxifen's effectiveness in these 
women. 
Royal Marsden Trial 
The Royal Marsdan Hospital randomized controlled trial18 compared 
tamoxifen (20mg per day) for 8 eight years with placebo in women with a family 
history of breast cancer. It was designed as a pilot study for the International 
Breast Cancer Intervention Study. Of 1200 women randomized to treatment, over 
570 ofthem discontinued the medication and only 79 completed 8 years of 
treatment at the time the results were published, at an average of 70 months of 
follow-up. Although this study did not find a difference between the groups 
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(RR=l.06, 95% CI, 0.7-1.7), it was likely underpowered to detect a difference 
even if one exists. 
Other reasons why the Royal Marsden results differed from the BCPT 
results are probably attributable to the differing study populations. The women in 
this trial were high risk because of a family history of breast cancer. In fact, over 
half of the patients in the treatment group had a first degree relative diagnosed 
with breast cancer prior to age 50. Genetic risk factors are more likely to be 
associated with estrogen-receptor negative tumors, which tamoxifen would be 
ineffective against. Subjects in the BCPT were more likely to be high risk 
because of nongenetic risk factors, which are more often associated with estrogen-
receptor positive tumors. Finally, about half of the women in the Royal Marsden 
trial took hormone replacement therapy at some point while enrolled in the trial. 
International Breast Cancer Intervention Study 
The International Breast Cancer Intervention Study (IBIS-1 )19 randomized 
7000 high-risk women to tamoxifen (20mg per day) for 5 years or placebo. The 
complex inclusion criteria included combinations of family history, hormonal 
factors and previous biopsy-proven diagnosis of ADH or LCIS that placed women 
at significantly elevated risk for breast cancer. Participants were allowed to take 
HRT. This study found a 32% risk reduction in the treatment group (RR=0.68, 
95% CI,O.S-0.92). They also found a 31% reduction in benign breast disease and 
a 32% reduction in breast pain. There was no difference in risk reduction based 
on age, degree of risk, or HRT use. 
13 
There was a significant increase in thromboembolic events and a non-
significant increase in endometrial cancer in the treatment group. There was no 
difference in the incidence of cataracts or fractures. Of note in this study, there 
was a statistically significant increase in all-cause mortality in the tarnoxifen 
group. This result is different from the BCPT and the Italian trials, which found 
non-significant decreases in all-cause mortality. The increased deaths were 
attributable to many different causes, leading the investigators to speculate that 
this finding may be due to chance. 
Italian Tamoxifen Prevention Study 
The Italian tarnoxifen trial20 randomized 5200 women at low-to-average 
risk of breast cancer to treatment with tarnoxifen or placebo. Inclusion criteria 
demanded that the woman be post-hysterectomy; 49% also had bilateral 
salpingoophorectomy. At a mean follow-up of over 80 months, there was no 
difference in breast cancer incidence between the two groups (p=0.215). 
Participants were allowed to take HRT. There was a significant difference in 
breast cancer events between the HRT users in the tamoxifen group (0.92%) and 
the HRT users in the control group (2.58%). This study was hampered by a high 
attrition rate and fewer-than-expected breast cancer events, which probably left it 
underpowered to detect a difference even if one exists. However, given that this 
represents a lower-than-average risk population, tarnoxifen use for 
chemoprevention of breast cancer is not likely appropriate. 
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Multiple Outcomes of Raloxifene Evaluation 
Raloxifene is a selective estrogen receptor modulator similar to tamoxifen. 
The major difference is that in addtion to having antiestrogenic effects on the 
breast, it also has antiestrogenic effects on the uterus. The Multiple Outcomes of 
Raloxifene Evaluation21 considered breast cancer incidence as one of multiple 
outcomes. The trial randomized 7700 North American and European 
postmenopausal women with osteoporosis to one of three arms: placebo; 
raloxifene 60mg for 3 years; or raloxifene 120mg for three years. The primary 
endpoint was fracture occurrence. 
The MORE trial found a significant decrease in the incidence of invasive 
breast cancer (RR=0.24, 95%CI, 0.13-0.44). The decrease was seen in ER+ but 
not in ER- tumors. There was an increase in thromboembolic events, but no 
increase in endometrial cancer. The breast cancer risk reduction was similar with 
60mg and 120mg doses ofraloxifene. The NSABP is currently conducting a 
randomized controlled trial comparing tamoxifen and raloxifene. The Study of 
Tamoxifen and Raloxifene (STAR) trial will enroll 22,000 women and results are 
expected in 2008. 
Meta-analysis 
In 2003 the investigators associated with the Royal Marsdan and Italian 
studies published a meta-analysis of the five studies outlined above.Z2 Overall, 
breast cancer incidence decreased 38% (95% CI 28-46%). The risk reduction was 
confined to ER+ tumors. There was no effect on ER- tumors. There was no 
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difference in risk reduction based on age. The risk of endometrial cancer was 2.4 
(95% CI, 1.5-4.0), and the increased risk was most prominent in women over 50 
years of age. Thromboembolic events also increased (RR 1.9, 95% CI 1.4-2.6). 
Incidence of fractures was not evaluated. There was no effect on all-cause 
mortality, but there was an increase in death from pulmonary embolism in women 
treated with tamoxifen. 
BREAST CANCER RISK 
Risk assessment 
For decades, investigators have tried to estimate an individual woman's 
risk for developing breast cancer. However, breast cancer risk assessment is an 
imperfect science. The tool most commonly used to assess breast cancer risk is 
the model developed at the National Cancer Institute. 23 Gail eta!. developed the 
model using case control data from the Breast Cancer Detection and 
Demonstration Project. The model includes age, age at menarche, age at first live 
birth, age at menopause, number of first-degree relatives with breast cancer and 
number of previous breast biopsies. It was later modified to include race and 
history of ADH. It is not appropriate to use the Gail model for women with a 
history of breast biopsy revealing LCIS; they are by definition high-risk. 
The Gail model was validated recently in a sample of women from the 
Nurses Health Study.24 The model predicted risk well in at the population level, 
although risk was underpredicted in younger women. The model was less 
effective at predicting individual risk. That is, it has poor "discriminatory 
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accuracy" at the individual level. If the Gail model is considered as a diagnostic 
test for future development of breast cancer, it has a sensitivity of 0.44 and a 
specificity of 0.66. While it does perform better than chance, it is a poor predictor 
of whether or not an individual woman with a given set of risk factors will 
actually develop breast cancer. This is one of the fundamental difficulties in 
applying population based risk assessment tools to individuals. 
One of the challenges for advocates of chemoprevention is to better 
identify those women who may benefit from treatment. While attempting to 
develop a risk/benefit index, Gail et al.25 found that tamoxifen was most 
beneficial for women less than 50 years old with a 5-year risk greater than 1.5%. 
They conclude that "tamoxifen causes very few adverse events among black and 
white women under age 50 years and has the potential to prevent invasive breast 
cancers and in situ breast cancers among high-risk women in this age range." 
The breast cancer risk prediction models currently in use do not attempt to 
discriminate between those who will developER+ tumors and those who will 
develop ER- tumors. Veronesi et al.26 used the results of the Italian Tamoxifen 
Trial to attempt to determine a risk profile that predicts the development of an 
ER+ tumor. They found a subset of breast cancer patients (13% of the total 
sample) with a profile that placed them at "high-risk" for ER+ tumors. The risk 
factors included height above 62 inches, age at menarche less than or equal to 13, 
age at first birth greater than or equal to 24, overall parity, and the presence of 
ovaries. Tamoxifen decreased the incidence of breast cancer in this high-risk 
group by 81%. 
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Although the results ofthis subset analysis need to be repeated in other 
populations, this is intriguing information. If we were better able to predict who 
might get an ER+ breast cancer, we could restrict the use oftamoxifen to those 
women who have a higher likelihood of benefit. This would increase the cost-
effectiveness of the drug and may tilt the risk/benefit ratio toward overall benefit. 
High risk 
The defmition of "high-risk" for breast cancer varies. Family history, 
hormonal factors and known genetic mutations can all increase a woman's risk of 
breast cancer, as can previous breast biopsies revealing proliferative changes. 
definition of high risk used in the BCPT- age greater than or equal to 35 and 5- I FDA approval of tamoxifen for breast cancer risk reduction is based on the 
year risk greater than 1.66%. This is a somewhat arbitrary definition of high risk, 
based on statistical power calculations for the BCPT. Regardless, any woman 
with a biopsy revealing atypical hyperplasia or LCIS should be considered at 
increased risk for the future development of breast cancer. 
Women who have a mutation in the BRCAl or BRCA2 gene are at very 
high risk of developing breast cancer. Their absolute lifetime risk is 80-85%. 
Tamoxifen has not been studied for breast cancer prevention is this group. 
However, a case-control study showed that it does offer protection against 
subsequent contralateral breast cancer following diagnosis of breast cancer. Risk 
was decreased 62% in BRCAl carriers and 37% in BRCA2 carriers. The effect 
oftamoxifen was independent of oophorectomy?7 
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POTENTIAL PUBLIC HEALTH BENEFIT 
Estimates of the potential public health benefit of chemoprevention for 
breast cancer vary widely. The wide variation in estimates is largely attributable 
to differing assessments of the number of women who would have a favorable 
risk/benefit profile. The National Cancer Institute used results from the Cancer 
Control Module of the National Health Interview Survey to estimate that 15.5% 
of US women aged 35-79 years would be eligible fortamoxifen based on a 5-year 
risk of greater than 1.5%. They then used a risk/benefit tool created by Gail et al. 
based on the results of the BCPT to create an overall risk/benefit index. About 
5% of white women (2.4 million women) have a positive risk/benefit ratio. They 
estimate that 28,500 cases of invasive breast cancer could be prevented over 5 
years.Z5 
This estimate differs from the estimate by the authors of the BCPT, who 
calculated that 700,000 cases of invasive and in situ breast cancers could be 
prevented in 5 years. The estimate is based on the assumption that all US women 
who meet eligibility criteria for the BCPT take the full 5-year course, regardless 
of the woman's potential for adverse events.Z8 
Using a cohort from the Nurses Health Study and very conservative 
criteria to estimate who might have a net health benefit from tamoxifen, one 
group concluded that only 3.3% of cases of invasive breast cancer arose from 
women who would have benefited from tamoxifen. Therefore, only 1.6-1. 7% of 
breast cancers would be prevented by 5 years oftamoxifen.24 
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In a survey of North Carolina primary care offices, 7-10% of women age 
40-69 were identified as appropriate for counseling about tamoxifen use. These 
women had both a 5-year risk greater than or equal to 1.66% and a low risk of 
adverse events. Also, 9% reported a history of an abnormal breast biopsy. These 
authors found that a primary care provider can screen for women who are at high 
risk by asking about family history and history of biopsy. A woman who answers 
yes to one of these questions should undergo formal risk assessment using the 
Gail model. By their estimates, only 6-8% of all breast cancers among women 
age 40-69 could be prevented with 5 years of tamoxifen treatment.29 This 
• 
In an attempt to further define potential benefits of tamoxifen for breast I 
represents a very conservative estimate, in that any woman with hypertension or 
diabetes was considered to be at high risk for adverse events. 
cancer chemprevention, Col et al. 30 used a patient-specific Markov modeling 
strategy to calculate gains in life expectancy in women aged 50 or older. For 
women without a uterus, gains in life-expectancy were two to six months, 
depending on breast cancer risk. For women with a uterus, there were smaller 
gains; depending on breast and endometrial cancer risk factors, some losses in life 
expectancy were noted. The potential gains in life expectancy for 
postmenopausal women at high risk for breast cancer compare favorably to other 
preventive measures. For example, manunographic screening every other year 
from age 50 to age 60 results in average gains of 0.8 months. Cervical cancer 
screening every three years leads to life-expectancy gains of three months. 
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TABLE 2: NUMBER NEEDED TO TREAT WITH TAMOXIFEN FOR 5 
YEARS TO PREVENT ONE CASE OF BREAST CANCER 
Average High Highest 
BREAST CANCER RISK (5-year = 0.99%) (5-year = 1.66%) (5-year = 3.18%) 
NNT 85 51 
The NNT to mduce one case of endometnal cancer m women at average nsk for 
endometrial cancer is 208. 
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Another potential benefit of tamoxifen for breast cancer chemoprevention 
involves reducing the morbidities and costs associated with the diagnosis and 
follow-up of benign breast disease in a high-risk population. Benign breast 
disease in this population has both economic and psychological consequences. In 
the BCPT, there was a decrease in invasive breast cancer, in situ breast cancer and 
benign breast disease. There was a 36% reduction in atypical hyperplasia. The 
annual rate of breast cancer in women with atypical hyperplasia was 10 per 1000 
women in the placebo group, and 4 per 1000 in the treatment group. 15 This 
implies that tamoxifen effects breast carcinogenesis at an early, preventive phase 
and also at a later, treatment phase. 
CURRENT RECOMMENDATIONS 
A search of theN ational Guidelines Clearinghouse and Medline indicates 
that the following are the available recommendations for chemoprevention 
counseling and use. 
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The United States Preventive Services Task Force31 recommends that 
clinicians discuss chemoprevention with women both at high risk for breast 
cancer and at low risk for adverse effects. These women should be informed of 
potential benefits as well as potential risks. This is a grade B recommendation. 
They do not recommend chemoprevention for low-to-average risk women. While 
chemoprevention may have some benefit for these women, the risks outweigh the 
benefits. The Canadian Task Force on Preventive Health Care offers similar 
recommendations. 
The American Society for Clinical Oncologl2 says that tamoxifen (20mg 
per day for 5 years) may be offered for risk reduction in women who have a 5-
year risk greater than or equal to 1.66%. The best risk/benefit profile is seen in 
premenopausal women, those who have had a hysterectomy, or those who are at 
higher risk. They state that the discussion of chemoprevention should involve 
informed decision making and should attempt to define individual risks and 
benefits. Use oftamoxifen with HRT and use of other chemopreventive agents 
such as raloxifene, aromatase inhibitors or fenretinide is not recommended 
outside of a clinical trial. 
The National Comprehensive Cancer Network33 recommends that risk 
reduction therapy counseling should be offered to women with a 5-year risk 
greater than or equal to 1. 7% who have a life expectancy of more than I 0 years 
and no contraindications to tamoxifen. Contraindications to tamoxifen listed are: 
history ofDVT, PE, stroke or TIA; concurrent estrogen and/or progestin use; 
pregnancy; and pregnancy potential without effective contraception. 
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THE SURGEON'S ROLE 
The surgeon's role in the care of breast patients is multifaceted. Women 
with benign breast complaints such as pain or fibrocystic changes are often 
referred to surgeons for clinical breast exam and follow-up. Women with breast 
masses are seen in consultation by surgeons and undergo radiographic 
examination to determine the need for biopsy. Women with mammographic 
abnormalities either see a surgeon for open or percutaneous core breast biopsy, or 
see a radiologist for percutaneous core breast biopsy. Women with genetic 
mutations are referred to surgeons for discussion of prophylactic mastectomies. 
And, the surgeon is involved in the initial and long-term care of breast cancer 
patients. 
In this study, we are particularly interested in women who undergo breast 
biopsy and are found to have atypical hyperplasia or LCIS - those women whose 
biopsy results do not reveal cancer but do reveal lesions that place them at high 
risk for the future development of breast cancer. Each of those women should be 
cared for by a surgeon at some point during her care. 
Radiologists perform percutaneous core breast biopsies in some 
communities. These are biopsies done for nonpalpable mammographic 
abnormalities. About 5% of these biopsies will reveal ADH. On average, 16% 
(range 10-25%) of percutaneous biopsies that reveal ADH will be upstaged to 
cancer on open biopsy. Therefore, women who have percutaneous biopsies 
showing ADH should always be referred to a surgeon for open surgical biopsy?4 
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Other studies in the surgery, radiology and pathology literature support this 
recommendation. 
It is also unlikely that a woman with one of the pathologic entities of 
interest, atypical hyperplasia or LCIS, would be cared for exclusively by a 
primary care provider. Family practitioners routinely perform aspiration of breast 
cysts. However, guidelines indicate that women with solid rather than cystic 
breast lesions should be referred to a surgeon?5 
Given that women who have breast biopsies with atypical hyperplasia or 
LCIS are at increased risk for breast cancer and that chemoprevention studies 
show that they benefit from tamoxifen, and given that the surgeon who performs 
the breast biopsy has the first opportunity to discuss chemoprevention, we sought 
to determine the practice patterns of North Carolina surgeons with respect to 
breast cancer chemoprevention in these high risk women. 
MATERIALS AND METHODS 
Subject Selection 
The subjects in this study are general surgeons living in North Carolina 
and licensed to practice by the North Carolina Medical Board. Subjects were 
recruited from the list of all general surgeons licensed by the North Carolina 
Medical Board, as listed on the North Carolina Health Professions Data System 
list maintained by the Cecil G. Sheps Center for Health Services Research. 
The inclusion criteria for this study are as follows: Currently a resident of 
North Carolina; licencsed to practice medicine by the North Carolina Medical 
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Board; listed on the NC Health Professions Data System list maintained by the 
Cecil G. Sheps Center for Health Services Research; and self-reported specialty as 
"surgeon- general" or "surgeon- oncology." All other medical specialties were 
excluded from this study. In the data analysis, we excluded those respondents 
whose practice does not include breast care. 
Research Protocol 
This is a single-center cross-sectional, descriptive study based on a self-
administered questionnaire. Subjects were asked to complete one survey, 
expected to take 10-15 minutes to complete. An initial letter and survey were 
mailed to all general surgeons licensed by the North Carolina Medical Board; they 
were sent to the address provided on the NC Health Professions Data System list 
maintained at the Sheps Center. Three weeks later, a reminder post card was sent 
to those subjects who had not responded. Three weeks after that, a follow-up 
letter and another copy of the survey were sent to non-respondents. A follow-up 
letter communicating the results of the survey will be sent to all of the general 
surgeons on the NC Health Professions Data System list to whom the original 
survey was sent. 
The survey consisted of two pages of questions. It was designed 
specifically for this study and pilot tested on a small group of general surgeons 
and surgical oncologists. See Appendix. 
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This protocol was declared exempt from Institutional Review Board 
review by the Institutional Review Board of the School of Medicine at the 
University of North Carolina at Chapel Hill. 
Data Analysis 
Data collected include practice type and location, residency and post-
residency training, age, gender, amount of practice devoted to breast disease, i 
familiarity with chemoprevention studies and chemoprevention guidelines, and 
practice patterns and referral patterns for follow-up of chemoprevention. The 
demographic data were included in the NC Health Professions Data Set and are 
available for both respondents and nomespondents. 
Univariate analysis will be performed to describe rates of 
chemoprevention counseling and prescribing. Bivariate analysis will examine 
relationships between chemoprevention counseling/prescribing and other factors 
such as volume of breast care, practice type, participation in multidisciplinary 
clinics or tumor boards, and surgeon factors like age, gender, and post-residency 
training. If bivariate analyses reveal any significant associations, linear/logistic 
regression will be performed as appropriate. 
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RESULTS 
TABLE 3: CHARACTERISTICS OF SURGEONS AND THEIR 
PRACTICE SETTINGS 
Respondents Nonrespondents 
N= (%) N= (%) 
PHYSICIAN CHARACTERISTICS I 
. .. 
Gender (Male) 
Race (White) 
Board Certified 
Fellowship Training 
Medical School Affiliation 
Age > or = 50 years 
PRACTICE CHARACTERISTICS · . 
. ·. 
. 
. . 
Metropolitan Location 
Practice Type 
Solo 
Single Specialty Group 
Multispecialty Group 
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TABLE 4: CHEMOPREVNTION PRACTICES 
N= (%) 
Surgeons who counsel about chemoprevention 
Surgeons who refer for counseling 
Surgeons who prescribe chemoprevention 
Surgeons who refer for chemoprevention prescriptions 
Once data collection is complete, we may anticipate the following results: 
1. Surgeons are not discussing chemoprevention with high risk patients OR 
2. Surgeons discuss or recommend chemoprevention but do not prescribe it OR 
3. Surgeons discuss and prescribe chemoprevention OR 
4. Surgeons prescribe raloxifene rather than tamoxifen 
DISCUSSION 
If North Carolina surgeons are counseling high risk women about breast 
cancer chemoprevention and prescribing chemoprevention, it would be 
worthwhile to repeat this study in a national sample. It is well established that 
there is regional variation in the surgical treatment of breast cancer; there may be 
regional variation in chemoprevention practices as well. It would also be 
interesting to assess if there are differences in chemoprevention practices between 
general surgeons and those with additional training in surgical oncology. It is 
28 
unlikely that our North Carolina sample will have adequate power to detect this 
difference. 
Even if women at high risk for the future development of breast cancer are 
being appropriately counseled, patient reluctance to take tamoxifen may be a 
barrier to the effectiveness of chemoprevention. In a single-institution study of 43 
women eligible to take tamoxifen, only two were treated. After undergoing a 
neutral (although not standardized) physician administered educational session 
about tamoxifen, 15 women declined immediately and the 26 who were initially 
undecided eventually declined. Most declined because of a fear of side effects or 
a reluctance to discontinue HRT. Perhaps most interestingly, after the educational 
session, more than half were able to accurately describe the risk reduction, but 
73% substantially overestimated the risk of complications?6 
If we find that North Carolina general surgeons are recommending 
chemoprevention but not prescribing it, two questions will need to be answered. 
First, to whom are these patients referred? Referral patterns may vary in 
different communities; women may be referred to their primary care providers, 
obstetrician/gynecologists, medical oncologists, or others. Second, are the 
patients actually receiving the chemoprevention medication? In 2001, 56% of 
community physicians in North Carolina were not familiar with using the Gail 
model for breast cancer risk prediction and 69% were not comfortable discussing 
tamoxifen with high risk women. (Kinsinger, personal communication) 
We may find that surgeons are not discussing chemoprevention with these 
high risk patients. A discussion of chemoprevention options is complicated and 
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time consuming. There may be a need for an educational intervention to increase 
surgeons' familiarity with chemoprevention trial results and current 
recommendations. Communicating individual risk to patients is difficult because 
the tools we have are imperfect and because both doctors and patients have a hard 
time understanding risk. Several studies have shown that women tend to 
overestimate their breast cancer risk in particular?7 
In a community based sample of 1273 North Carolina women aged 40-55 
years insured by Blue Cross/Blue Shield, 23% of women reported that they would 
be interested in taking a drug to prevent breast cancer. Only 8% of this sample 
would potentially be eligible for tamoxifen, using a 5-year Gail risk score of 
i > 1.66% to define eligibility. However, interest in chemoprevention was not associated with actual risk of breast cancer; it was associated with perceived risk. 
t 
Thus, interest in chemoprevention appears to arise more from worry than from 
actual risk.38 This study underscores the importance of appropriately counseling 
those women who would benefit from chemoprevention while also allaying the 
fears of those who are not actually at high risk. 
Finally, we may find that surgeons are discussing and prescribing 
chemoprevention, but that they tend to use raloxifene rather than tamoxifen. This 
would also necessitate an educational intervention. There are a variety of reasons 
why tamoxifen is preferable to raloxifene at this point in time. While breast 
cancer was a carefully assessed outcome on the MORE trial and the results are 
likely to be true, it was a secondary endpoint. Currently, tamoxifen has an FDA 
indication for breast cancer risk reduction but raloxifene does not. Those 
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guidelines that address the question reconunend raloxifene only within a clinical 
trial. Perhaps most importantly, tamoxifen's effectiveness has been replicated in 
multiple studies, while there is only one study to support the use of raloxifene. 
Until results of ongoing trials such as STAR and RUTH (Raloxifene Use for The 
Heart) offer more evidence for the use of raloxifene, tamoxifen will remain the 
standard of care. 
There are unresolved issues regarding chemoprevention of breast cancer. 
The effect on mortality is unknown; longer follow-up of the randomized trials will 
allow us to assess disease-specific and overall mortality. Adjuvant studies offer 
convincing evidence for the optimal length of treatment, but the optimal dose of 
tamoxifen for prevention, the minimum effective dose, is unknown. The length of 
ongoing effect is also unknown; adjuvant studies indicate that tamoxifen' s 
protective effect continues for 5-l 0 years after the 5 years of treatment. Questions 
of generalizability to average-risk women and those with BRCAl and BRCA2 
mutations persist. Although minority enrollment in the BCPT was low, results 
from adjuvant studies with 10-15% minority enrollment indicate that there were 
similar decreases in contralateral tumors in whites and blacks. 
While the overall public health benefit of breast cancer chemoprevention 
is still debated, it is clear that chemoprevention offers benefit to some subsets of 
women at high risk for the future development of breast cancer. Advice from 
surgeons about chemoprevention use following breast biopsy is likely to be 
important in the patient's decision to use chemoprevention. There is no evidence 
available in the medical literature about the surgeon's effect in this particular 
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situation. It is known that primary care physician recommendation was the most 
important factor in a woman's decision to enroll in the BCPT?9 The surgeon's 
recommendation to women with breast cancer regarding treatment with breast 
conserving therapy versus modified radical mastectomy is one of the most 
powerful factors in her decision.4° Finally, surgeons play a key role in the 
recruitment of breast cancer patients to adjuvant therapy clinical trials.41 
I 
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Please circle the number next to the answer that most accurately reflects your beliefs and practice patterns. 
Please return this questionnaire no later than MMIDDNYYY. Thank you for your help. 
I. Approximately what percentage of your practice is breast surgery? 
(0) None 
(I) 1-20% 
(2) 21-40% 
(3) 41-60% 
(4) 61-80% 
(5)>80% 
IF YOU ANSWERED "NONE" TO QUESTION #I, PLEASE STOP NOW AND RETURN YOUR 
SURVEY IN THE ENCLOSED SELF-ADDRESSED ENVELOPE. YOUR RESPONSE IS IMPORTANT 
TO US. THANK YOU. 
2. Approximately how many breast biopsies do you perform in an average month? __ 
3. Of those breast biopsies, approximately what percentage are atypical ductal hyperplasia, atypical lobular 
hyperplasia or LCIS? 
(0) 0-5% 
(!) 6-10% 
(2) 11-15% 
(3) 16-20% 
(4)>20% 
4. As a surgeon, do you think you have a role in discussing breast cancer chemoprevention with patients (ie. 
the use oftamoxifen, raloxifene, or other medications for the prevention of breast cancer)? 
(0) No role 
(I) Minor role 
(2) Some role 
(3) Major role 
5. Do you bring up the topic of breast cancer chemoprevention with patients who have biopsies that show 
ADH, ALH or LCIS? 
(0) Never 
(!)Rarely 
(2) Sometimes 
(3) Often 
(4)Aiways 
6. If you DO NOT bring up the topic of chemoprevention with a specific patient, do you ask another 
healthcare provider to discuss chemoprevention? 
(0) Never (I) Rarely 
(2) Sometimes 
(3) Often 
(4) Always 
Which healthcare provider do you ask to discuss chemoprevention with 
these patients? (You may choose more than one answer) 
(!)Family Practice (4) OB/GYN 
(2) Internal Medicine (5) Other _____ _ 
(3) Medical Oncology 
7. How often do patients ask you about breast cancer chemoprevention? 
(0) Never 
(I) Less often than once a month 
(2) About once a month 
(3) Between once a week and once a month 
(4) One time per week or more 
8. Are you comfortable discussing chemoprevention with those patients who bring it up? 
(3) Very comfortable (I) Not very comfortable 
(2) Somewhat comfortable (0) Not comfortable at all 
9. As a surgeon, do you think you have 
(3) Major role 
(2) Some role 
If you are NOT comfortable discussing chemoprevention, to 
whom do you refer these patients? (You may choose more than 
one answer) 
(I) Family Practice 
(2) Internal Medicine 
(3) Medical Oncology 
(4)0B/GYN 
(5) Other ----------
in prescribing breast cancer chemoprevention drugs? 
(I) Minor role 
(0) No role 
If it IS NOT your role to prescribe chemoprevention, who 
should prescribe these drugs? (You may choose more than one 
answer) 
(I) Family Practice 
(2) Internal Medicine 
(3) Medical Oncology 
(4)0B/GYN 
(5) Other _________ _ 
10. If you DO prescribe chemoprevention, approximately how many women have you prescribed it for in 
the last 6 months? 
---
11. If you DO prescribe chemoprevention, which drug(s) do you prescribe? (You may choose more than one 
answer) 
( 0) Tamoxifen 
( 1) Raloxifene 
(2) Other _____ _ 
12. How familiar are you with the results ofthe NSABP P-1 Breast Cancer Prevention Trial, the randomized 
controlled trial oftamoxifen for breast cancer prevention? 
(0) Not at all familiar (2) Somewhat familiar 
(I) Not very familiar (3) Very familiar 
13. To whom do you look for national recommendations regarding breast cancer prevention? (You may 
choose more than one answer) 
(I) American College of Surgeons 
(2) American Cancer Society 
(3) National Cancer Institute 
( 4) National Comprehensive Cancer Network 
(5) Society of Surgical Oncology 
(6) US Preventive Services Task Force 
(7) Other ________ _ 
14. Do you routinely participate in a multidisciplinary breast cancer clinic or tumor board? 
(0) Never 
(1) Occasionally 
(2) Sometimes 
(3) Ahnost always 
(4) Always 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE. PLEASE RETURN IT IN THE 
ENCLOSED SELF-ADDRESSED, STAMPED ENVELOPE BY MMIDD!YYYY. 
